# A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)

> **NCT01235507** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 71 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** methotrexate
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01235507
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2014-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235507, "A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01235507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*